schizophrenia Archives - Cambridge Cognition

Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development

23 April 2024 / News

Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced a further £0.5 million grant […]

Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development Read More »

Digital measures to advance research & quality of life in schizophrenia

5 March 2024 / eBooks & Whitepapers, Publications & posters

Schizophrenia spectrum disorders are complex and serious psychiatric disorders with multifaceted symptoms and associated difficulties, including psychosis, negative symptoms (e.g., loss of motivation), cognitive dysfunction, and functional impairment in major life areas. This multifaceted clinical picture in schizophrenia is also heterogeneous, both across individuals and within individuals over time, posing a challenge for studying groups

Digital measures to advance research & quality of life in schizophrenia Read More »

Measuring functional outcomes in schizophrenia in an increasingly digital world

6 May 2022 / Insights

Insights Back to resource centre 9 August 2022 Generating and validating Verbal Paired Associates word-pair lists for automated testing These posters were presented at the Alzheimer’s Association International Conference on Tuesday 2nd August and Wednesday 3rd August 2022. See below for a summary and to read the full posters. Poster summariesMemorability of Word-Pairs: Developing a Method for Generation of Calibrated

Measuring functional outcomes in schizophrenia in an increasingly digital world Read More »

Hazardous drinking and cognition in schizophrenia, schizoaffective disorder and bipolar disorder

6 April 2022 / Insights

Insights Back to resource centre 6 April 2022 Hazardous drinking and cognition in schizophrenia, schizoaffective disorder and bipolar disorder We recently caught up with Atiqul Haq Mazumder, a doctoral researcher at the University of Oulu, Finland. Here, he tells us about how he used CANTAB to understand more about whether hazardous drinking could affect cognition in people with schizophrenia, schizoaffective

Hazardous drinking and cognition in schizophrenia, schizoaffective disorder and bipolar disorder Read More »

Are memory impairments in early and chronic schizophrenia related to the volume of particular hippocampal subfields?

17 September 2019 / Insights

Insights Back to resource centre 17 September 2019 Are memory impairments in early and chronic schizophrenia related to the volume of particular hippocampal subfields? Cassandra Wannan, final year PhD student at the University of Melbourne, shared the role that CANTAB played in her latest publication: Hippocampal subfields and visuospatial associative memory across stages of schizophrenia-spectrum disorder. Can you tell us

Are memory impairments in early and chronic schizophrenia related to the volume of particular hippocampal subfields? Read More »

Affective face processing in schizophrenia: disorder-specific or transdiagnostic deficit?

6 April 2018 / Insights

Insights Back to resource centre 6 April 2018 Affective face processing in schizophrenia: disorder-specific or transdiagnostic deficit? Our recent review of meta-analyses concluded that facial emotion recognition deficits are common across a range of psychiatric, neurological and developmental disorders. Our Senior Scientist, Dr Jack Cotter, presented the latest findings at Schizophrenia International Research Society (SIRS) conference. BackgroundSocial cognitive dysfunction is

Affective face processing in schizophrenia: disorder-specific or transdiagnostic deficit? Read More »